NuGenea
Pre-clinical- Indications
- Inflammatory diseases
Company intelligence / Profile preview
Ludwig Enterprises has developed a non-invasive cheek swab test using 48 mRNA biomarkers analyzed by proprietary machine learning algorithms. Their lead program, Revealia™, is in the final validation phase before commercial launch as an early screening tool for multiple cancers—demonstrating high sensitivity and specificity in over 3,300 patient samples across 40 U.S. medical centers. They are also funding preclinical research into exosome-based targeted drug delivery for incurable brain cancers[5][6].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ludwig Enterprises, Inc..